Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Long-Term Investments (2016 - 2024)

Gsk has reported Long-Term Investments over the past 10 years, most recently at $123.2 million for Q4 2024.

  • Quarterly results put Long-Term Investments at $123.2 million for Q4 2024, up 80.5% from a year ago — trailing twelve months through Dec 2024 was $123.2 million (up 80.5% YoY), and the annual figure for FY2024 was $123.2 million, up 80.5%.
  • Long-Term Investments for Q4 2024 was $123.2 million at Gsk, up from $68.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for GLAXF hit a ceiling of $1.7 billion in Q4 2022 and a floor of $6.6 million in Q4 2020.
  • Median Long-Term Investments over the past 5 years was $68.3 million (2023), compared with a mean of $388.6 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 98.36% in 2020 and later soared 6991.46% in 2022.
  • Gsk's Long-Term Investments stood at $6.6 million in 2020, then skyrocketed by 267.51% to $24.3 million in 2021, then soared by 6991.46% to $1.7 billion in 2022, then crashed by 96.03% to $68.3 million in 2023, then soared by 80.5% to $123.2 million in 2024.
  • The last three reported values for Long-Term Investments were $123.2 million (Q4 2024), $68.3 million (Q4 2023), and $1.7 billion (Q4 2022) per Business Quant data.